Hypertension Management in Patients with Chronic Kidney Disease

Introduction to Antihypertensive Regimen Modification

• The American College of Cardiology recommends modifying the current antihypertensive regimen by continuing ACE inhibitors, such as lisinopril, but replacing thiazide diuretics, like hydrochlorothiazide, with a loop diuretic due to declining kidney function (eGFR 38 mL/min/1.73m²) in patients with chronic kidney disease (CKD) and diabetes 1, 2

ACE Inhibitor Therapy

• The American Journal of Kidney Diseases recommends continuing ACE inhibitor therapy as first-line agents for patients with diabetes and CKD, providing renoprotection by reducing intraglomerular pressure and proteinuria, with a strong recommendation (1B) for patients with albuminuria ≥300 mg/24h 2, 3
• ACE inhibitors or ARBs are recommended as first-line therapy for hypertensive patients with CKD, with a suggested use (2C/2D) for patients with albuminuria 30-300 mg/24h 3

Diuretic Therapy

• Thiazide diuretics should be replaced with a loop diuretic when eGFR falls below 30-40 mL/min/1.73m², as they lose effectiveness at this level, with the European Heart Journal supporting the use of loop diuretics in patients with CKD and diabetes, targeting a BP of <130/80 mmHg 2, 4
• The following table summarizes the recommended diuretic therapy:

Blood Pressure Targets

• The American College of Cardiology recommends a target BP of <130/80 mmHg for patients with diabetes and CKD, supported by evidence showing reduced cardiovascular events and slower progression of kidney disease, while the Kidney International guidelines recommend a target BP of <140/90 mmHg for patients without albuminuria and <130/80 mmHg for patients with albuminuria (≥30 mg/24h) 1, 2, 4, 5, 3

Additional Therapies

• The Journal of the American Society of Nephrology suggests considering adding a third agent, such as a dihydropyridine calcium channel blocker (e.g., amlodipine 5-10mg daily), if BP remains uncontrolled, as most patients with CKD require multiple agents (3-4) to reach target BP, with a suggested addition of dihydropyridine calcium channel blocker as second-line agent and thiazide/thiazide-like diuretic as third-line agent 6

Monitoring and Follow-up

• The Annals of Internal Medicine recommends monthly evaluation of adherence and therapeutic response until BP control is achieved, with regular assessment of albuminuria and monitoring of eGFR trend every 3-6 months, and checking serum creatinine and potassium within 2-4 weeks of initiating ACE-I/ARB, with a rise in creatinine up to 30% being acceptable and not a reason to discontinue therapy 1, 3
• The American Society of Nephrology recommends checking urine albumin-to-creatinine ratio from spot urine sample to evaluate for albuminuria, with albuminuria ≥30 mg/24h indicating kidney damage, and stratification as follows: 30-300 mg/24h (moderately increased) and >300 mg/24h (severely increased) 5, 3

Avoiding Therapeutic Inertia

• The American College of Cardiology advises against delaying the addition of additional agents if BP remains uncontrolled, and the American Journal of Kidney Diseases recommends against discontinuing ACE inhibitors if creatinine rises <30% from baseline, as they provide superior renoprotection compared to other antihypertensive classes in diabetic nephropathy 1, 2
• Inappropriate discontinuation of ACE-I/ARB when mild creatinine elevation occurs, and failure to monitor renal function and electrolytes after starting therapy, can lead to inadequate BP control and therapeutic inertia, with the Kidney International guidelines recommending against dual RAS blockade (combination of ACE-I + ARB) and monitoring for hyperkalemia with ACE-I/ARB, especially with reduced GFR 6, 7, 3